Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, cemiplimab (Libtayo®) cannot be endorsed for use within NHS Wales for use as a monotherapy for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI). |
||
|
||
Medicine details |
||
| Medicine name | cemiplimab (Libtayo®) | |
| Formulation | 350 mg concentrate for solution for infusion | |
| Reference number | 4923 | |
| Indication | Monotherapy for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI) |
|
| Company | Regeneron Pharmaceuticals Inc | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 23/02/2022 | |